As the pharmaceutical industry churns out more cancer treatments, a new analysis finds that oncologists who receive payments over an extended period of time — mostly for speaking or consulting — are much more likely to prescribe a medicine made by the company that writes them a check.

The physicians treating kidney and lung cancer as well as chronic myeloid leukemia typically wrote more prescriptions for drugs made by a company that paid them over a three-year period, according to the findings, which were published in The Oncologist. However, a cause-and-effect relationship was not established and the same sort of association was not found among doctors who treated prostate cancer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • There is an old saying “Propinquity breeds attraction.” These payments may cause a focus that keeps the Rx more in mid, giving more opportunity to find value in the treatment. (One that is stronger than simply the ‘food and beverage’ one.)
    As a quasi-cynic, I would further postulate that the flow of information would tend to focus on value / safety, rather than ‘merely anecdotal’ reports of side effects? Or at least, one would wonder.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy